Atwater Malick’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Atwater Malick’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-25	Closed	–	–	217
2019 Q3	$0	Buy	+25	New	+$13	﹤0.01%	220

Other funds holding GCVRZ

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Atwater Malick's GCVRZ Position: Q4 2019 in Review

Atwater Malick sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2019, closing a stake of 25 shares.

Atwater Malick first reported a position in GCVRZ in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2019.

Atwater Malick reported no remaining Sanofi Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
Atwater Malick sold 25 Sanofi Contingent Value Rights shares in Q4 2019.
Atwater Malick first reported a position in Sanofi Contingent Value Rights in Q3 2019 and held it in 1 quarter.
Atwater Malick's Sanofi Contingent Value Rights position peaked at $0 in Q3 2019.
103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2019.

Based on Atwater Malick's 13F filing for Q4 2019, filed 7 Jan 2020.